Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Peter M. Haddad & Christoph U. Correll. (2023) Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. Expert Opinion on Pharmacotherapy 24:4, pages 473-493.
Read now
Read now
V. Yu. Skryabin, M. A. Vinnikova, E. V. Ezhkova, M. S. Titkov & R. A. Bulatova. (2021) Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study. Journal of Addictive Diseases 39:4, pages 513-525.
Read now
Read now
Georgios D. Kotzalidis, Chiara Rapinesi, Chiara Chetoni & Sergio De Filippis. (2021) Aripiprazole IM depot as an option for the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy 22:11, pages 1407-1416.
Read now
Read now
Fabio Magliocco, Renato de Filippis, Matteo Aloi, Filippo Antonio Staltari, Raffaele Gaetano, Cristina Segura-Garcia & Pasquale De Fazio. (2020) Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study. International Journal of Psychiatry in Clinical Practice 24:2, pages 201-207.
Read now
Read now
Articles from other publishers (27)
Antonello Bellomo, Lucia Armini, Edwige Cuozzo, Laura De Masi, Fiammetta Gallone, Giuseppe Valentini Gravinese, Giuseppe Tricarico & Antonio Ventriglio. (2023) Descriptive analysis of pathways to Care and Rehabilitation among Psychiatric Offenders after the closing of Forensic Psychiatric Hospitals in Italy. RIVISTA SPERIMENTALE DI FRENIATRIA 147:1, pages 87-102.
Crossref
Crossref
Anna Maria Auxilia, Massimiliano Buoli, Alice Caldiroli, Greta Silvia Carnevali, Agnese Tringali, Roberto Nava, Massimo Clerici & Enrico Capuzzi. (2023) High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders. Biomedicines 11:2, pages 314.
Crossref
Crossref
Howard C. Margolese, Matthieu Boucher, Francois Therrien & Guerline Clerzius. (2022) Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study. BMC Psychiatry 22:1.
Crossref
Crossref
Markku Lähteenvuo, Jurjen J. Luykx, Heidi Taipale, Ellenor Mittendorfer-Rutz, Antti Tanskanen, Albert Batalla & Jari Tiihonen. (2022) Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts. The British Journal of Psychiatry 221:6, pages 758-765.
Crossref
Crossref
Pierre-Michel Llorca, Philippe Nuss, Éric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, Stéphane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-Noëlle Vacheron & Jean-Michel Azorin. (2022) Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC Psychiatry 22:1.
Crossref
Crossref
Ashley N. Nilson, Daniel E. Felsing & John A. Allen. 2022. GPCRs as Therapeutic Targets. GPCRs as Therapeutic Targets
677
731
.
Giovanni Martinotti, Stefania Chiappini, Alessio Mosca, Andrea Miuli, Maria Chiara Santovito, Mauro Pettorruso, Valentin Skryabin, Stefano L. Sensi & Massimo Di Giannantonio. (2022) Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical
Practice. Current Pharmaceutical Design 28:27, pages 2241-2259.
Crossref
Crossref
M. Finnegan, J. McLoughlin, E. Bainbridge, D. McGuinness, B. Hallahan & C. McDonald. (2022) Quality of life after involuntary psychiatric admission. International Journal of Law and Psychiatry 83, pages 101810.
Crossref
Crossref
Marianna Mazza, Emanuele Caroppo, Giuseppe Marano, Georgios D. Kotzalidis, Carla Avallone, Giovanni Camardese, Delfina Janiri, Lorenzo Moccia, Alessio Simonetti, Luigi Janiri & Gabriele Sani. (2022) Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series. International Journal of Environmental Research and Public Health 19:12, pages 7397.
Crossref
Crossref
Pavel Mohr, Jirí Masopust & Miloslav Kopeček. (2022) Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?. Frontiers in Psychiatry 12.
Crossref
Crossref
Alexandria S. Coles, Dunja Knezevic, Tony P. George, Christoph U. Correll, John M. Kane & David Castle. (2021) Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review. Frontiers in Psychiatry 12.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Mariangela Corbo, Giovanni Martinotti, Andrea Aguglia, Virginio Salvi, Andrea Amerio, Salvatore Calò, Laura Fusar‐Poli, Gianluca Serafini, Maria Signorelli, Mario Amore, Claudio Mencacci, Guido Di Sciascio, Giovanni Biggio, Eugenio Aguglia & Massimo Di Giannantonio. (2021) Long‐acting second‐generation and oral antipsychotics for substance use disorders and psychotic symptoms: Prescribing attitudes among Italian psychiatrists. Perspectives in Psychiatric Care 57:4, pages 1700-1706.
Crossref
Crossref
Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar & Prakash S. Masand. (2021) Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?. Clinical Psychopharmacology and Neuroscience 19:3, pages 434-448.
Crossref
Crossref
Giovanni OstuzziFederico BertoliniCinzia Del GiovaneFederico TedeschiChiara BovoChiara GastaldonMichela NoséFilippo OgheriDavide PapolaMarianna PurgatoGiulia TurriniChristoph U. CorrellCorrado Barbui. (2021) Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. American Journal of Psychiatry 178:5, pages 424-436.
Crossref
Crossref
Claudia Carmassi, Francesca Milani, Carlo Antonio Bertelloni, Enrico Massimetti, Angelo Cerù & Liliana Dell’Osso. (2020) Comparing re‐hospitalisation rates in a real‐world naturalistic 24‐month follow‐up of psychotic patients with different treatment strategies: Oral versus LAI antipsychotics. International Journal of Clinical Practice 75:3.
Crossref
Crossref
José Manuel Olivares, Ana González-Pinto & Mario Páramo. (2021) Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. European Psychiatry 64:1.
Crossref
Crossref
Marian S. McDonagh, Tracy Dana, Shelley Selph, Emily B. Devine, Amy Cantor, Christina Bougatsos, Ian Blazina, Sara Grusing, Rongwei Fu & Daniel W. Haupt. (2020) Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia. Psychiatric Research and Clinical Practice 2:2, pages 76-87.
Crossref
Crossref
Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis & Francisco Arias. (2020) Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - Real World Outcomes 7:1, pages 75-83.
Crossref
Crossref
Amal Abdel‐Baki, Dominic Thibault, Sofia Medrano, Emmanuel Stip, Martin Ladouceur, Ramzan Tahir & Stephane Potvin. (2019) Long‐acting antipsychotic medication as first‐line treatment of first‐episode psychosis with comorbid substance use disorder. Early Intervention in Psychiatry 14:1, pages 69-79.
Crossref
Crossref
S. De Filippis, E. Amici, G. Callovini, G. Giordano, I. Cuomo, F. Perrini, A. Carannante, L. Tomassini & G.D. Kotzalidis. (2019) P.703 Comparative effects of aripiprazole once-monthly and paliperidone palmitate long-acting injectables on patients’ psychopathology, functioning, and quality of life. European Neuropsychopharmacology 29, pages S475-S476.
Crossref
Crossref
Shih-Fen Chen & Yu-Chih Shen. (2019) Long-Acting Injectable Aripiprazole for a Schizophrenic Patient Concomitant With Stimulant Use Disorder. Journal of Clinical Psychopharmacology 39:5, pages 508-509.
Crossref
Crossref
Chiara Rapinesi, Georgios D. Kotzalidis, Lorenzo Mazzarini, Roberto Brugnoli, Stefano Ferracuti, Sergio De Filippis, Ilaria Cuomo, Gloria Giordano, Antonio Del Casale, Gloria Angeletti, Gabriele Sani & Paolo Girardi. (2019) Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review. Clinical Drug Investigation 39:8, pages 713-735.
Crossref
Crossref
Isabella Pacchiarotti, Jari Tiihonen, Georgios D. Kotzalidis, Norma Verdolini, Andrea Murru, José Manuel Goikolea, Marc Valentí, Alberto Aedo & Eduard Vieta. (2019) Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. European Neuropsychopharmacology 29:4, pages 457-470.
Crossref
Crossref
Qian Cai, Charmi Patel, Edward Kim, Nancy Connolly, Ozgur Tunceli & Antoine C. El Khoury. (2019) Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Advances in Therapy 36:4, pages 858-869.
Crossref
Crossref
N. N. Ivanets, M. A. Vinnikova, E. V. Ezhkova, M. S. Titkov & R. A. Bulatova. (2019) Aripiprazole and quetiapine in the treatment of patients with 'dual diagnosis' of schizophrenia and drug addiction. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:9, pages 52.
Crossref
Crossref
Massimo Clerici, Andrea de Bartolomeis, Sergio De Filippis, Giuseppe Ducci, Icro Maremmani, Giovanni Martinotti & Fabrizio Schifano. (2018) Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice. Frontiers in Psychiatry 9.
Crossref
Crossref